Ruxolitinib and methylprednisolone for treatment of patients with relapsed/refractory multiple myeloma

Results from the I-RUX Study published online in the British Journal of Haematology WEST HOLLYWOOD, Calif., Dec. 20, 2022 /PRNewswire/ -- ONCOtherapeutics and Dr. James Berenson published promising new data demonstrating that ruxolitinib (RUX), an oral JAK1/2 inhibitor, with only...

Click to view original post